Nanogen Reaches Milestone in CDC Influenza Project
Nanogen has delivered the second phase milestone requirements, including the point-of-care prototype device to detect influenza viruses rapidly in clinical samples, to the Centers for Disease Control and Prevention (CDC).
Nanogen, together with business partner HX Diagnostics, had been awarded a contract from the CDC to fund an accelerated multiphase development plan for a rapid diagnostic test for pandemic flu.
The company said delivery of the prototype device is an important milestone demonstrating the feasibility of meeting the CDC’s specifications for the rapid test. Nanogen is continuing product development and initiating clinical trials with further funding of the project pending approval by the CDC.